Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.
SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (DMD)
- SGT-003 continues to be well tolerated in the first four patients dosed in the ongoing INSPIRE DUCHENNE clinical trial.
- Patient enrollment and dosing under the expanded INSPIRE DUCHENNE protocol is ongoing.
- Six clinical sites are activated in North America (five in the U.S., one in Canada).
- The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) cleared the INSPIRE DUCHENNE clinical trial application (CTA) with initial site activation expected in 2H 2025.
- Solid expects to report data from the first three patients dosed in Q1 2025.
Learn More: Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
- Follow Us -
